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ABSTRACT
A new series of 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives were designed, synthesised, and eval-
uated to assess their inhibitory effect on the human monoamine oxidase (hMAO) A and B isoforms.
Different (un)substituted (hetero)aromatic substituents were linked to N1 of the hydrazone in order to
establish robust structure–activity relationships. The results of the biological testing demonstrated that the
presence of the hydrazothiazole nucleus bearing at C4 a phenyl ring functionalised at the meta position
with a nitro group represents an important pharmacophoric feature to obtain selective and reversible
human MAO-B inhibition for the treatment of neurodegenerative disorders. In addition, the most potent
and selective MAO-B inhibitors were evaluated in silico as potential cholinesterase (AChE/BuChE) inhibitors
and in vitro for antioxidant activities. The results obtained from molecular modelling studies provided
insight into the multiple interactions and structural requirements for the reported MAO inhibi-
tory properties.
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1. Introduction
Neurodegenerative disorders (NDDs) are primarily characterised by
an extensive loss of neurons in specific areas of the brain underly-
ing a progressive decline in motor and cognitive functions. The
patients suffering from NDDs share a large plethora of pathogenic
mechanisms and symptomatology1. To overcome such multifactor-
ial diseases, an effective approach should consider molecules able
to modulate different pathways. These scaffolds must be chosen
among those recognised to interact pleiotropically with important
and crucial systems such as monoamine oxidase (MAO-A and
MAO-B), cholinesterases [acetylcholinesterase (AChE) and butyryl-
cholinesterase (BuChE)], and ROS producers. The same molecule,
endowed with a multi-target activity and characterised chemically
and physically, could represent an innovative advance for the
treatment of complex NDDs2. Among NDDs, Parkinson’s disease
(PD) is of much interest to researchers involved in the design and
synthesis of multi-target-direct ligands in the last few years3,4.
Among the several proposed scaffolds, we recently explored thia-
zolylhydrazones as dual-target-directed agents which acts at both
MAO-B and AChE, while also possessing antioxidative effects5,6.
These compounds displayed very potent inhibitory activity and
selectivity against the human monoamine oxidase (hMAO)-B iso-
form and discrete AChE inhibition and ROS scavenging effects.
Human MAOs are of great medicinal importance due to their
unique role in modulating the function/activity of specific
neurotransmitters (i.e. dopamine) in various pathogenic cental ner-
vous system (CNS) conditions (PD, mood disorders, anxiety and
depression, migraine, aggressive behaviour)7–13. Particularly, the
expression of the MAO-B isoform in human brain increases with
age and has been linked to neurodegeneration, a process which
may be attributed to glial cell proliferation (where it is mainly
localised) as a result of neuronal loss in specific CNS regions. An
excessive dopamine turnover catalyzed by MAO-B with conse-
quent hydrogen peroxide-mediated production of ROS and react-
ive final products (aldehydes and ammonia) further links MAO-B
to neurodegeneration14.
Selective MAO-B inhibitors could thus restore the dopamine
concentration in the basal ganglia and limit ROS-induced neuro-
toxicity as well-recognised for the clinically used drugs in this class
(selegiline, rasagiline, safinamide)15,16
Previous studies have also shown the correlation between
MAO-B and Alzheimer’s disease (AD) due to (i) the increase of
MAO-B activity in brain and platelets in AD patients, (ii) the MAO-
B specific ligand 11C-deuterium-L-deprenyl showed enhanced
binding in presymptomatic familial AD patients, and (iii) AD
patients are characterised by enhanced astrocytosis. Moreover,
MAO-B was reported to be associated with c-secretase in the
regulation of intraneuronal Ab levels especially in pyramidal neu-
rons as well as glia cells in the frontal cortex and hippocampus17.
However, the main pathogenic feature linked with the progression
of AD is the weakening of the cholinergic system in the brain and
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inhibitors of AChE and BuChE are approved as a therapeutic strat-
egy to limit the symptoms and progression of AD. The role of
BuChE is not completely known yet.
Recently, we designed and synthesised multi-target inhibitors
based on thiazol-2-ylhydrazone scaffold with selective MAO-B
inhibitory potency for further structural tuning18–25. Pursuing our
efforts in the discovery and development of new thiazolylhydra-
zones effective against NDDs, we extended our study by evaluat-
ing derivatives 1–37, in order to evaluate their hMAOs inhibition
profile, chelating properties, antioxidant activity as well as in silico
AChE and BuChE inhibition properties. These activities determine
the efficacy of these compounds to work as multi-target drugs.
2. Chemistry
4–(3-Nitrophenyl)thiazol-2-ylhydrazone derivatives (1–36) were
synthesised in high yields as reported in our previous communica-
tions (Scheme 1)26. The appropriate carbonyl compound was
reacted with thiosemicarbazide in ethanol at room temperature
and in presence of acetic acid as the catalyst (Scheme 1, a). The
Hantzsch reaction between the resulting thiosemicarbazone and
2-bromo-30-nitroacetophenone in the same conditions of solvent
and temperature gave the corresponding 4–(3-nitrophenyl)thiazol-
2-ylhydrazone derivatives (Scheme 1, b). For the synthesis of the
thiophene-containing 4-(3-amino)thiazol-2-ylhydrazone derivative
(37), reduction of the nitro group was performed using sodium
dithionite previously solubilised in a basic aqueous solution and
added dropwise to a stirring suspension of compound 3 in tetra-
hydrofuran at room temperature (Scheme 1, c). All the synthesised
products were washed with petroleum ether and diethyl ether
and purified by chromatography using silica gel as stationary
phase and the appropriate mixtures of ethyl acetate and petrol-
eum ether as mobile phase. Characterisation and purity assess-
ment of the synthesised compounds were carried out by melting
point determination, spectroscopic methods (IR, 1H and 13C NMR)
and elemental analysis.
3. Biological characterisation
Compounds 1–37 were evaluated in vitro as potential inhibitors of
the two human recombinant isoforms of monoamine oxidase
(hMAO-A and hMAO-B). For a selected compound, the reversibil-
ity/irreversibility of MAO inhibition and mechanism of inhibition
(e.g. competitive) were evaluated. Furthermore, with the aim to
explore the multi-target profile of these derivatives, we performed
tests to determine chelating properties, antioxidant activity as well
as the AChE and BuChE inhibition profile.
4. Experimental protocols
Starting materials and reagents used in the synthetic procedures
were obtained from commercial suppliers and were used with-
out further purification. Solvents were freshly distilled before
use whenever required. All melting points were measured on a
StuartVR melting point apparatus SMP1, and are uncorrected. IR
spectra were measured with a PerkinElmer Spectrum 100 FT-IR
spectrophotometer equipped with universal total reflectance
(ATR) accessory with absorption frequencies expressed in recip-
rocal centimetres. 1H and 13 C NMR spectra were recorded at
400MHz on a Bruker spectrometer using CDCl3 and DMSO-d6 as
the solvents at room temperature. The samples were analyzed
at a final concentration of 30mg/mL. Chemical shifts are
Scheme 1. General structure showing the chemical modification made and synthesis of 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives 1–36 and 4–(3-aminophe-
nyl)thiazol-2-ylhydrazone derivative 37.
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expressed as d units (parts per millions) relative to the solvent
signal. Coupling constants J are valued in Hertz (Hz). The proc-
essing and analyses of the NMR data were carried out with
MestreNova. Elemental analyses for C, H, and N were recorded
on a Perkin-Elmer 240 B microanalyzer obtaining analytical
results within ± 0.4% of the theoretical values for all com-
pounds. All reactions were monitored by thin layer chromatog-
raphy (TLC) performed on 0.2mm thick silica gel-aluminium
backed plates (60 F254, Merck). Preparative flash column chro-
matography was carried out on silica gel (230–400 mesh, G60
Merck). All compounds were recrystallised from ethanol. The
yields shown are not optimised. Organic solutions were dried
over anhydrous sodium sulphate. Evaporation of the solvent
after reaction was carried out on a rotary evaporator (Buchi R-
210, Milan, Italy).
4.1. General synthetic procedure for the nitro compounds 1–36
and amino compound 37
To a stirring solution of the appropriate carbonyl compound (1.0
eq.) in ethanol (50ml), thiosemicarbazide (1.0 eq.) and acetic acid
as the catalyst were added. The reaction was monitored by TLC
up to completion, usually reached in 24–72 h. The obtained sus-
pension was filtered, and the solid washed twice with petroleum
ether (20ml) and diethyl ether (20ml). The thiosemicarbazone (1.0
eq.), thus synthesised, was reacted with 2-bromo-30-nitroacetophe-
none previously dissolved in ethanol (50ml), and the reaction was
magnetically stirred at room temperature until completion as
monitored by TLC. The resulting 4–(3-nitrophenyl)thiazol-2-ylhy-
drazone derivative was collected by filtration, washed with petrol-
eum ether (20ml) and diethyl ether (20ml), and purified by
column chromatography using ethyl acetate:petroleum ether as
mobile phase, to give compounds 1–37 in high yields and purity.
With respect to the synthetic approach of compound 36 that is
the product of the dimerisation of the parent compound 31, two
equivalents of thiosemicarbazide were used in the first step
(Scheme 1, a) and two equivalents of 2-bromo-30-nitroacetophe-
none were used in the second step (Scheme 1, b). To obtain the
thiophene containing 4-(3-amino)thiazol-2-ylhydrazone derivative
(37), sodium dithionite (5.5 eq) was dissolved in a basic solution
of water (30ml) and sodium bicarbonate (5.5 eq.). The resulting
solution was added dropwise to a stirring suspension of nitro
compound 3 (1.0 eq.) in tetrahydrofuran (50ml) at room tempera-
ture and the reaction was stirred for 2 h (up to completion by
TLC). The tetrahydrofuran was evaporated in vacuo, the solid that
precipitated from the aqueous phase was collected by filtration,
washed with water (20ml) and petroleum ether (20ml), and dried
to give the desired amino derivative 37. In order to confirm struc-
ture and purity of the synthesised test compounds, characterisa-
tion was performed using IR, 1H NMR and 13C NMR along with
elemental analysis. Melting points were recorded as mp range.
The synthesised compounds exist in theory as a mixture of E and
Z isomers. However, the chemical-physical data are characteristic
for the most predominant and thermodynamically stable E geo-
metric isomer because of the up-shielding observed in the 1H
NMR spectra for the NH signal and for the absence of any Z-stabil-
ising functional groups. The Z isomer is also undesirable due to
steric interaction between the aryl group and the NH moiety27. In
general, the IR spectrum (neat) for derivatives 1–37 showed
stretching absorption bands at approximately 3310 cm1 for NH,
at 3040 cm1due to the stretching of Csp2-H, at 1640 cm
1 for the
C¼N and at 1585 and 1445 cm1 for C¼C.
4.1.1. 1-(Furan-2-ylmethylene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hy-
drazine (1)
Green powder, mp 213–215 C, 71% yield; 1H NMR (400MHz,
DMSO-d6): d 6.60–6.61 (m, 1H, furan), 6.82–6.83 (m, 1H, furan),
7.64 (s, 1H, C5H-thiazole), 7.65–7.70 (m, 1H, furan), 7.79–7.81 (m,
1H, Ar), 7.93 (s, 1H, Ar), 8.14–8.16 (m, 1H, Ar), 8.29–8.31 (m, 1H,
Ar), 8.65 (s, 1H, ¼CH), 12.17 (bs, 1H, NH, D2O exch.). Anal. Calcd
for C14H10N4O3S: C, 53.50; H, 3.21; N, 17.82. Found: C, 53.26; H,
3.01; N, 17.99.
4.1.2. 1-(1-(Furan-2-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-
yl)hydrazine (2)
Yellow powder, mp 230–234 C, 68% yield; 1H NMR (400MHz,
DMSO-d6): d 2.28 (s, 3H, CH3), 7.38–7.47 (m, 2H, furan), 7.64 (s, 1H,
C5H-thiazole), 7.66–7.75 (m, 1H, furan), 7.87–7.89 (m, 1H, Ar),
8.15–8.18 (m, 1H, Ar), 8.32–8.35 (m, 1H, Ar), 8.74 (s, 1H, Ar), 11.52
(bs, 1H, NH, D2O exch.). Anal. Calcd for C14H10N4O2S2: C, 54.87; H,
3.68; N, 17.06. Found: C, 55.06; H, 3.51; N, 17.22.
4.1.3. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(thiophen-2-ylmethylene)-
hydrazine (3)
Yellow powder, mp 187–189 C, 70% yield; 1H NMR (400MHz,
DMSO-d6): d 7.09–7.11 (m, 1H, thiophene), 7.37–7.38 (m, 1H, thio-
phene), 7.58–7.60 (m, 1H, thiophene), 7.64 (s, 1H, C5H-thiazole),
7.68–7.72 (t, 1H, Ar), 8.13–8.15 (m, 1H, Ar), 8.23 (s, 1H, Ar),
8.28–8.30 (m, 1H, Ar), 8.66 (s, 1H, ¼CH), 12.19 (bs, 1H, NH, D2O
exch.). 13C NMR (101MHz, DMSO-d6): d 106.9 (Ar-C5, thiazole),
120.4 (Ar), 122.5 (Ar), 129.8 (Ar, thiophene), 130.7 (Ar), 132.0 (Ar),
134.0 (Ar, thiophene), 136.6 (Ar), 137.5 (Ar, thiophene), 139.5 (Ar,
thiophene), 145.9 (C¼N), 148.2 (Ar-NO2), 148.8 (Ar-C4, thiazole),
168.7 (C¼N, thiazole). Anal. Calcd for C14H10N4O2S2: C, 50.90; H,
3.05; N, 16.96. Found: C, 51.13; H, 2.88; N, 17.20.
4.1.4. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)ethylide-
ne)hydrazine (4)
Yellow powder, mp 270–272 C, 74% yield; 1H NMR (400MHz,
DMSO-d6): d 2.34 (s, 3H, CH3), 7.05–7.07 (m, 1H, thiophene),
7.35–7.41 (m, 1H, thiophene), 7.44–7.50 (m, 1H, thiophene), 7.65
(s, 1H, C5H-thiazole), 7.69–7.71 (m, 1H, Ar), 8.11–8.14 (m, 1H, Ar),
8.31–8.35 (m, 1H, Ar), 8.70 (s, 1H, Ar), 11.41 (bs, 1H, NH, D2O
exch.). 13C NMR (101MHz, DMSO-d6): d 15.0 (CH3), 107.4 (Ar-C5,
thiazole), 120.4 (Ar), 122.5 (Ar), 127.1 (Ar, thiophene), 128.1 (Ar, thi-
ophene), 128.4 (Ar, thiophene), 130.7 (Ar), 132.0 (Ar), 136.7 (Ar),
143.7 (Ar, thiophene), 144.6 (C¼N), 148.5 (Ar-NO2), 148.8 (Ar-C4,
thiazole), 168.7 (C¼N, thiazole). Anal. Calcd for C15H12N4O2S2: C,
52.31; H, 3.51; N, 16.27. Found: C, 52.05; H, 3.78; N, 16.43.
4.1.5. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(thiophen-3-yl)ethylide-
ne)hydrazine (5)
Yellow powder, mp 183–185 C, 85% yield; 1H NMR (400MHz,
CDCl3): d 2.39 (s, 3H, CH3), 7.07 (s, 1H, C5H-thiazole), 7.36–7.38 (m,
1H, Ar), 7.57 (s, 1H, thiophene), 7.61–7.65 (m, 2H, thiophene),
8.16–8.22 (m, 2H, Ar), 8.66 (s, 1H, Ar), 9.49 (bs, 1H, NH, D2O exch.).
13C NMR (101MHz, DMSO-d6): d 15.2 (CH3), 107.2 (Ar-C5, thiazole),
120.4 (Ar), 122.4 (Ar), 124.7 (Ar, thiophene), 125.7 (Ar, thiophene),
127.3 (Ar, thiophene), 130.7 (Ar), 132.0 (Ar), 136.7 (Ar), 141.7 (Ar,
thiophene), 144.6 (C¼N), 148.5 (Ar-NO2), 148.8 (Ar-C4, thiazole),
168.7 (C¼N, thiazole). Anal. Calcd for C15H12N4O2S2: C, 52.31; H,
3.51; N, 16.27. Found: C, 52.60; H, 3.27; N, 16.02.
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4.1.6. 1-(1-(5-Chlorothiophen-2-yl)ethylidene)-2-(4-(3-nitrophenyl)
thiazol-2-yl)hydrazine (6)
Orange powder, mp 227–229 C, 81% yield; 1H NMR (400MHz,
DMSO-d6): d 2.29 (s, 3H, CH3), 7.09 (s, 1H, C5H-thiazole), 7.26–7.29
(m, 1H, Ar), 7.67–7.73 (m, 2H, thiophene), 8.14–8.32 (m, 2H, Ar),
8.70 (s, 1H, Ar), 11.58 (bs, 1H, NH, D2O exch.). Anal. Calcd for
C15H11ClN4O2S2: C, 47.55; H, 2.93; N, 14.79. Found: C, 47.71; H,
3.17; N, 14.53.
4.1.7. 1-Benzylidene-2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazine (7)
Yellow powder, mp 193–195 C, 76% yield; 1H NMR (400MHz,
DMSO-d6): d 7.38–7.47 (m, 3H, Ar), 7.67–7.74 (m, 3H, Ar), 8.06 (s,
1H, C5H-thiazole), 8.15–8.17 (m, 1H, Ar), 8.30–8.32 (m, 1H, Ar),
8.41–8.43 (m, 1H, Ar), 8.69 (s, 1H, ¼CH), 12.31 (bs, 1H, NH, D2O
exch.). Anal. Calcd for C16H12N4O2S: C, 59.25; H, 3.73; N, 17.27.
Found: C, 58.99; H, 3.98; N, 17.02.
4.1.8. 1-(2-Nitrobenzylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydra-
zine (8)
Orange powder, mp 228–230 C, 79% yield; 1H NMR (400MHz,
DMSO-d6): d 7.63–7.65 (m, 1H, Ar), 7.73–7.74 (m, 2H, Ar), 7.79–7.82
(m, 1H, Ar), 8.04–8.05 (m, 1H, Ar), 8.06 (s, 1H, C5H-thiazole),
8.16–8.18 (m, 1H, Ar), 8.31–8.33 (m, 1H, Ar), 8.45–8.47 (m, 1H, Ar),
8.69 (s, 1H, ¼CH), 12.68 (bs, 1H, NH, D2O exch.). 13C NMR
(101MHz, DMSO-d6): d 107.6 (Ar-C5, thiazole), 120.4 (Ar), 122.6
(Ar), 125.2 (Ar), 128.0 (Ar), 128.9 (Ar), 130.3 (Ar), 130.7 (Ar), 132.1
(Ar), 134.0 (Ar), 136.5 (Ar), 137.2 (Ar), 137.6 (C¼N), 147.9 (Ar-NO2),
148.8 (Ar-C4, thiazole), 168.6 (C¼N, thiazole). Anal. Calcd for
C16H11N5O4S: C, 52.03; H, 3.00; N, 18.96. Found: C, 52.27; H, 2.82;
N, 19.12.
4.1.9. 1-(3-Nitrobenzylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hydra-
zine (9)
Yellow powder, mp 222–224 C, 81% yield; 1H NMR (400MHz,
DMSO-d6): d 7.67–7.73 (m, 2H, Ar), 8.15 (s, 1H, C5H-thiazole),
8.17–8.31 (m, 6H, Ar), 8.66 (s, 1H, ¼CH), 11.62 (bs, 1H, NH, D2O
exch.). Anal. Calcd for C16H11N5O4S: C, 52.03; H, 3.00; N, 18.96.
Found: C, 52.21; H, 3.24; N, 18.74.
4.1.10. 1-(4-Nitrobenzylidene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hy-
drazine (10)
Characterisation data were in agreement with those reported in
the literature28.
4.1.11. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-phenylethylidene)hy-
drazine (11)
Yellow powder, mp 261–263 C, 86% yield; 1H NMR (400MHz,
DMSO-d6): d 2.34 (s, 3H, CH3), 7.38–7.45 (m, 3H, Ar), 7.67 (s, 1H,
C5H-thiazole), 7.69–7.73 (m, 1H, Ar), 7.77–7.80 (m, 2H, Ar),
8.13–8.16 (m, 1H, Ar), 8.31–8.33 (m, 1H, Ar), 8.72–8.73 (m, 1H, Ar),
11.36 (bs, 1H, NH, D2O exch.).
13C NMR (101MHz, DMSO-d6): d
14.6 (CH3), 107.3 (Ar-C5, thiazole), 120.5 (Ar), 122.4 (Ar), 126.2 (2 
Ar), 128.9 (2  Ar), 129.3 (Ar), 130.7 (Ar), 132.0 (Ar), 136.8 (Ar),
138.3 (Ar), 147.4 (C¼N), 148.6 (Ar-NO2), 148.8 (Ar-C4, thiazole),
170.6 (C¼N, thiazole). Anal. Calcd for C17H14N4O2S: C, 60.34; H,
4.17; N, 16.56. Found: C, 60.12; H, 4.32; N, 16.79.
4.1.12. 2-(4-(3-Nitrophenyl)thiazol-2-yl)-1-(1-phenylpropylidene)hy-
drazine (12)
Yellow powder, mp 215–217 C, 85% yield; 1H NMR (400MHz,
DMSO-d6): d 1.08–1.12 (t, 3H, CH3), 2.86–2.91 (m, 2H, CH2),
7.38–7.46 (m, 3H, Ar), 7.69 (s, 1H, C5H-thiazole), 7.70–7.74 (m, 1H,
Ar), 7.79–7.81 (m, 2H, Ar), 8.15–8.17 (d, J¼ 8.0 Hz, 1H, Ar),
8.32–8.34 (d, J¼ 8.0 Hz, 1H, Ar), 8.74 (s, 1H, Ar), 11.55 (bs, 1H, NH,
D2O exch.). Anal. Calcd for C18H16N4O2S: C, 61.35; H, 4.58; N, 15.90.
Found: C, 61.20; H, 4.32; N, 16.13.
4.1.13. 1-(1-(2-Nitrophenyl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-
2-yl)hydrazine (13)
Orange powder, mp 195–200 C, 87% yield; 1H NMR (400MHz,
DMSO-d6): d 2.34 (s, 3H, CH3), 7.61–7.65 (m, 2H, 1H Ar þ 1H C5H-
thiazole), 7.70–7.78 (m, 3H, Ar), 7.91–7.93 (m, 1H, Ar), 8.15–8.17
(m, 1H, Ar), 8.30–8.31 (m, 1H, Ar), 8.71 (s, 1H, Ar), 11.51 (bs, 1H,
NH, D2O exch.). Anal. Calcd for C17H13N5O4S: C, 53.26; H, 3.42; N,
18.27. Found: C, 53.11; H, 3.25; N, 18.54.
4.1.14. 1-(1-(3-Nitrophenyl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-
2-yl)hydrazine (14)
Orange powder, mp 214–216 C, 85% yield; 1H NMR (400MHz,
CDCl3): d 2.40 (s, 3H, CH3), 7.14 (s, 1H, C5H-thiazole), 7.61–7.63 (m,
2H, Ar), 8.15–8.26 (m, 4H, Ar), 8.63 (s, 1H, Ar), 8.70 (s, 1H, Ar), 8.98
(bs, 1H, NH, D2O exch.). Anal. Calcd for C17H13N5O4S: C, 53.26; H,
3.42; N, 18.27. Found: C, 53.55; H, 3.70; N, 18.09.
4.1.15. 1-(1-(4-Nitrophenyl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-
2-yl)hydrazine (15)
Orange powder, mp 258–260 C, 80% yield; 1H NMR (400MHz,
DMSO-d6): d 2.41 (s, 3H, CH3), 7.71–7.75 (m, 2H, 1H Ar þ 1H C5H-
thiazole), 8.02–8.05 (d, J¼ 8.8 Hz, 2H, Ar), 8.16–8.18 (m, 1H, Ar),
8.28–8.30 (d, J¼ 8.8 Hz, 2H, Ar), 8.32–8.35 (m, 1H, Ar), 8.74 (s, 1H,
Ar), 11.73 (bs, 1H, NH, D2O exch.). Anal. Calcd for C17H13N5O4S: C,
53.26; H, 3.42; N,18.27. Found: C, 53.01; H, 3.18; N, 18.43.
4.1.16. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(pyridin-2-ylmethylene)-
hydrazine (16)
Characterisation data were in agreement with those reported in
the literature29.
4.1.17. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(pyridin-3-ylmethylene)-
hydrazine (17)
Characterisation data were in agreement with those reported in
the literature30.
4.1.18. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(pyridin-4-ylmethylene)-
hydrazine (18)
Characterisation data were in agreement with those reported in
the literature31.
4.1.19. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(pyridin-2-yl)ethylide-
ne)hydrazine (19)
Characterisation data were in agreement with those reported in
the literature30.
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4.1.20. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(pyridin-3-yl)ethylide-
ne)hydrazine (20)
Characterisation data were in agreement with those reported in
the literature30.
4.1.21. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(pyridin-4-yl)ethylide-
ne)hydrazine (21)
Characterisation data were in agreement with those reported in
the literature30.
4.1.22. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(pyrazin-2-yl)ethylide-
ne)hydrazine (22)
Yellow powder, mp 243–245 C, 85% yield; 1H NMR (400MHz,
DMSO-d6): d 2.41 (s, 1H, CH3), 7.71–7.75 (m, 1H, Ar), 7.77 (s, 1H,
C5H-thiazole), 8.16–8.18 (m, 1H, Ar), 8.33–8.35 (m, 1H, Ar),
8.59–8.60 (m, 1H, Ar), 8.63–8.64 (m, 1H, Ar), 8.74–8.75 (m, 1H, Ar),
9.22–9.23 (m, 1H, Ar), 11.82 (bs, 1H, NH, D2O exch.). Anal. Calcd
for C15H12N6O2S: C, 52.93; H, 3.55; N, 24.69. Found: C, 53.20; H,
3.74; N, 24.84.
4.1.23. 1-((1H-Indol-3-yl)methylene)-2-(4-(3-nitrophenyl)thiazol-2-
yl)hydrazine (23)
Yellow powder, mp 253–255 C, 83% yield; 1H NMR (400MHz,
DMSO-d6): d 7.20–7.25 (m, 2H, Ar), 7.45–7.47 (m, 1H, Ar), 7.62 (s,
1H, C5H-thiazole), 7.70–7.74 (m, 1H, Ar), 7.79–7.80 (m, 1H, Ar),
8.15–8.17 (m, 1H, Ar), 8.23–8.25 (m, 1H, Ar), 8.29–8.33 (m, 2H, Ar),
8.70 (s, 1H, ¼CH), 11.55 (bs, 1H, NH-indole, D2O exch.), 11.98 (bs,
1H, NH, D2O exch.).
13C NMR (101MHz, DMSO-d6): d 106.0 (Ar-C5,
thiazole), 112.0 (Ar, indole), 112.4 (Ar, indole), 120.4 (Ar), 121.0 (Ar,
indole), 122.1 (Ar), 122.5 (Ar, indole), 123.1 (Ar, indole), 124.5 (Ar,
indole), 130.3 (Ar, indole), 130.7 (Ar), 132.1 (Ar), 136.6 (Ar), 137.6
(Ar, indole), 140.6 (C¼N), 148.0 (Ar-NO2), 148.7 (Ar-C4, thiazole),
168.7 (C¼N, thiazole). Anal. Calcd for C18H13N5O2S: C, 59.49; H,
3.61; N, 19.27. Found: C, 59.65; H, 3.39; N, 19.49.
4.1.24. 1-(1-(1H-Indol-3-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-
yl)hydrazine (24)
Green powder, mp 209–211 C, 87% yield; 1H NMR (400MHz,
DMSO-d6): d 2.36 (s, 3H, CH3), 7.25–7.28 (m, 2H, 1H C5H-thiazole þ
1H Ar), 7.43–7.47 (m, 1H, Ar), 7.63–7.90 (m, 3H, Ar), 8.12–8.21 (m,
1H, Ar), 8.31–8.50 (m, 2H, Ar), 8.78 (s, 1H, Ar), 11.08 (bs, 1H, NH-
indole, D2O exch.), 11.48 (bs, 1H, NH, D2O exch.). Anal. Calcd for
C19H15N5O2S: C, 60.46; H, 4.01; N, 18.56. Found: C, 60.70; H, 3.83;
N, 18.37.
4.1.25. 1-(Benzo[d][1,3]dioxol-5-ylmethylene)-2-(4-(3-nitrophe-
nyl)thiazol-2-yl)hydrazine (25)
Yellow powder, mp 255–256 C, 84% yield; 1H NMR (400MHz,
DMSO-d6): d 6.08 (s, 2H, OCH2O), 6.96–6.98 (m, 1H, Ar), 7.11–7.13
(m, 1H, Ar), 7.23 (s, 1H, Ar), 7.63 (s, 1H, C5H-thiazole), 7.68–7.72 (m,
1H, Ar), 7.96 (s, 1H, Ar), 8.13–8.15 (m, 1H, Ar), 8.28–8.30 (m, 1H,
Ar), 8.66 (s, 1H, ¼CH), 12.17 (bs, 1H, NH, D2O exch.). 13C NMR
(101MHz, DMSO-d6): d 101.9 (OCH2O, benzodioxole), 105.1 (Ar,
benzodioxole), 106.7 (Ar-C5, thiazole), 109.0 (Ar, benzodioxole),
120.4 (Ar), 122.4 (Ar), 122.7 (Ar, benzodioxole), 129.2 (Ar, benzo-
dioxole), 130.7 (Ar), 132.0 (Ar), 136.7 (Ar), 142.0 (C¼N), 148.4 (Ar-
NO2), 148.6 (Ar, benzodioxole), 148.7 (Ar-C4, thiazole), 149.0 (Ar,
benzodioxole), 169.1 (C¼N, thiazole). Anal. Calcd for C17H12N4O4S:
C, 55.43; H, 3.28; N, 15.21. Found: C, 55.22; H, 3.04; N, 15.39.
4.1.26. 1-(1-(Benzofuran-2-yl)ethylidene)-2-(4-(3-nitrophenyl)thia-
zol-2-yl)hydrazine (26)
Pink powder, mp 228–230 C, 81% yield; 1H NMR (400MHz,
DMSO-d6): d 2.37 (s, 3H, CH3), 7.25–7.29 (m, 1H, Ar), 7.31(s, 1H,
C5H-thiazole), 7.34–7.37 (m, 1H, Ar), 7.61–7.63 (m, 4H, Ar)
8.14–8.16 (m, 1H, Ar), 8.32–8.34 (m, 1H, Ar), 8.73 (s, 1H, Ar), 11.61
(bs, 1H, NH, D2O exch.).
13C NMR (101MHz, DMSO-d6): d 14.3
(CH3), 106.6 (Ar-C5, thiazole), 107.7 (Ar, benzofuran), 111.7 (Ar,
benzofuran), 120.5 (Ar), 122.0 (Ar, benzofuran), 122.5 (Ar), 123.8
(Ar, benzofuran), 125.9 (Ar, benzofuran), 128.6 (Ar, benzofuran),
130.7 (Ar), 132.0 (Ar), 136.7 (Ar), 139.1 (C¼N), 148.6 (Ar-NO2), 148.8
(Ar-C4, thiazole), 154.0 (Ar, benzofuran), 155.0 (Ar, benzofuran),
169.9 (C¼N, thiazole). Anal. Calcd for C19H14N4O3S: C, 60.31; H,
3.73; N, 14.81. Found: C, 60.07; H, 3.97; N, 15.00.
4.1.27. 1-(1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)ethylidene)-2-(4-
(3-nitrophenyl)thiazol-2-yl)hydrazine (27)
Orange powder, mp 242–244 C, 70% yield; 1H NMR (400MHz,
DMSO-d6): d 2.28 (s, 3H, CH3), 4.28 (s, 4H, benzodioxine), 6.89–6.91
(m, 1H, Ar), 7.27–7.29 (m, 2H, Ar), 7.66 (s, 1H, C5H-thiazole),
7.70–7.74 (t, 1H, Ar), 8.15–8.17 (m, 1H, Ar), 8.31–8.33 (m, 1H, Ar),
8.73 (s, 1H, Ar), 11.28 (bs, 1H, NH, D2O exch.).
13C NMR (101MHz,
DMSO-d6): d 14.5 (CH3), 64.5 (CH2), 64.7 (CH2), 107.2 (Ar-C5, thia-
zole), 114.9 (Ar, benzodioxine), 117.4 (Ar, benzodioxine), 119.5 (Ar,
benzodioxine), 120.4 (Ar), 122.4 (Ar), 130.7 (Ar), 131.6 (Ar, benzo-
dioxine), 132.0 (Ar), 136.7 (Ar), 143.6 (C¼N), 144.7 (Ar, benzodiox-
ine), 147.1 (Ar, benzodioxine), 148.5 (Ar-NO2), 148.7 (Ar-C4,
thiazole), 170.7 (C¼N, thiazole). Anal. Calcd for C19H16N4O4S: C,
57.57; H, 4.07; N, 14.13. Found: C, 57.80; H, 3.84; N, 58.02.
4.1.28. 1-(Naphthalen-1-ylmethylene)-2-(4-(3-nitrophenyl)thiazol-2-
yl)hydrazine (28)
Orange powder, mp 212–214 C, 72% yield; 1H NMR (400MHz,
DMSO-d6): d 7.59–7.63 (m, 2H, Ar), 7.67–7.75 (m, 3H, 2H Ar þ 1H
C5H-thiazole), 7.87–7.89 (d, J¼ 8.0 Hz, 1H, Ar), 7.99–8.03 (t, 2H, Ar),
8.16–8.18 (m, 1H, Ar), 8.33–8.35 (d, J¼ 8.0 Hz, 1H, Ar), 8.70–8.71
(m, 2H, 1H Ar þ 1H¼CH), 8.77–8.79 (d, J¼ 8.0 Hz, 1H, Ar), 12.52
(bs, 1H, NH, D2O exch.). Anal. Calcd for C20H14N4O2S: C, 64.16; H,
3.77; N, 14.96. Found: C, 63.92; H, 3.90; N, 15.12.
4.1.29. 1-(1-(Naphthalen-1-yl)ethylidene)-2-(4-(3-nitrophenyl)thia-
zol-2-yl)hydrazine (29)
White powder, mp 226–228 C, 74% yield; 1H NMR (400MHz,
DMSO-d6): d 2.33 (s, 3H, CH3), 7.54–7.59 (m, 4H, 3H Ar þ 1H C5H-
thiazole), 7.91–8.00 (m, 4H, Ar), 8.26–8.41 (m, 2H, Ar), 8.56–8.58
(m, 1H, Ar), 8.71–8.75 (m, 1H, Ar), 12.14 (bs, 1H, NH, D2O exch.).
Anal. Calcd for C21H16N4O2S: C, 64.93; H, 4.15; N, 14.42. Found: C,
65.10; H, 3.89; N, 14.21.
4.1.30. 1-(1-(Naphthalen-2-yl)ethylidene)-2-(4-(3-nitrophenyl)thia-
zol-2-yl)hydrazine (30)
Yellow powder, mp 152–154 C, 77% yield; 1H NMR (400MHz,
DMSO-d6): d 2.36 (s, 3H, CH3), 7.53–7.55 (m, 2H, Ar), 7.70–7.72 (m,
2H, 1H Ar þ 1H C5H-thiazole), 7.90–7.94 (m, 2H, Ar), 7.96–7.98
(m, 1H, Ar), 8.03–8.05 (m, 1H, Ar), 8.07–8.09 (m, 1H, Ar), 8.22–8.24
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(m, 1H, Ar), 8.41–8.43 (m, 1H, Ar), 8.74–8.75 (m, 1H, Ar), 11.54 (bs,
1H, NH, D2O exch.). Anal. Calcd for C21H16N4O2S: C, 64.93; H, 4.15;
N, 14.42. Found: C, 64.74; H, 4.36; N, 14.65.
4.1.31. 1-(1-(4-Acetylphenyl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-
2-yl)hydrazine (31)
Yellow powder, mp 205–207 C, 79% yield; 1H NMR (400MHz,
CDCl3): d 2.44 (s, 3H, CH3), 2.66 (s, 3H, CH3), 7.10 (s, 1H, C5H-thia-
zole), 7.64–7.66 (t, 1H, Ar), 7.90–7.92 (d, J¼ 8.4 Hz, 2H, Ar),
8.02–8.04 (d, J¼ 8.0 Hz, 2H, Ar), 8.15–8.17 (d, J¼ 6.8 Hz, 1H, Ar),
8.21–8.23 (d, J¼ 6.8 Hz, 1H, Ar), 8.65 (s, 1H, Ar), 10.15 (bs, 1H, NH,
D2O exch.).
13C NMR (101MHz, DMSO-d6): d 14.3 (CH3), 27.2 (CH3),
107.7 (Ar-C5, thiazole), 120.5 (Ar), 122.5 (Ar), 126.2 (2  Ar), 128.8
(2  Ar), 130.7 (Ar), 132.0 (Ar), 136.7 (Ar), 136.9 (Ar), 142.4 (C¼N),
146.0 (Ar-NO2), 148.8 (Ar-C4, thiazole), 170.3 (C¼N, thiazole), 197.9
(C¼O). Anal. Calcd for C19H16N4O3S: C, 59.99; H, 4.24; N, 14.73.
Found: C, 60.15; H, 4.03; N, 15.00.
4.1.32. 1-(Diphenylmethylene)-2-(4-(3-nitrophenyl)thiazol-2-yl)hy-
drazine (32)
Yellow powder, mp 166–168 C, 83% yield; 1H NMR (400MHz,
CDCl3): d 7.05 (s, 1H, C5H-thiazole), 7.39–7.43 (m, 5H, Ar), 7.62–7.67
(m, 6H, Ar), 8.14–8.25 (m, 2H, Ar), 8.58 (s, 1H, Ar), 10.15 (bs, 1H,
NH, D2O exch.).
13C NMR (101MHz, DMSO-d6): d 105.7 (Ar-C5, thia-
zole), 120.7 (Ar), 122.6 (Ar), 127.4 (2  Ar), 128.4 (2  Ar), 128.6 (2
 Ar), 129.7 (Ar), 129.8 (Ar), 130.0 (2  Ar), 130.2 (Ar), 131.5 (Ar),
131.6 (Ar), 135.3 (C¼N), 136.6 (Ar), 147.4 (Ar-NO2), 148.7 (Ar-C4,
thiazole), 168.8 (C¼N, thiazole). Anal. Calcd for C22H16N4O2S: C,
65.98; H, 4.03; N, 13.99. Found: C, 66.14; H, 4.21; N, 14.17.
4.1.33. 1-(1-(Coumarin-3-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-
2-yl)hydrazine (33)
Red powder, mp 183–185 C, 75% yield; 1H NMR (400MHz, DMSO-
d6): d 2.26 (s, 3H, CH3), 6.60 (s, 1H, C5H-thiazole), 6.86–6.87 (m, 1H,
Ar), 7.66–7.79 (m, 5H, Ar), 8.15–8.17 (m, 1H, Ar), 8.31–8.33 (m, 1H,
Ar), 8.72 (s, 1H, Ar), 11.35 (bs, 1H, NH, D2O exch.).
13C NMR
(101MHz, DMSO-d6): d 14.2 (CH3), 107.3 (Ar-C5, thiazole), 110.6
(Ar, coumarin), 112.3 (Ar, coumarin), 120.4 (Ar), 122.4 (Ar), 130.7
(Ar), 132.0 (Ar), 136.7 (Ar), 139.7 (Ar, coumarin), 144.6 (C¼N), 148.6
(Ar-NO2), 148.8 (Ar-C4, thiazole), 152.2 (C¼O, coumarin), 170.2
(C¼N, thiazole). Anal. Calcd for C20H14N4O4S: C, 59.11; H, 3.47; N,
13.79. Found: C, 58.94; H, 3.24; N, 13.98.
4.1.34. 1-(4-(3-Nitrophenyl)thiazol-2-yl)-2-(1-(phenanthren-3-yl)e-
thylidene)hydrazine (34)
Pink powder, mp 255–257 C, 72% yield; 1H NMR (400MHz,
DMSO-d6): d 1.24 (s, 3H, CH3), 7.25 (s, 2H, 1H Ar þ 1H C5H-thia-
zole), 7.37–7.48 (m, 5H, Ar), 7.61–7.69 (m, 5H, Ar), 8.01–8.03 (d,
J¼ 8.4 Hz, 2H, Ar), 11.40 (bs, 1H, NH, D2O exch.). Anal. Calcd for
C25H18N4O2S: C, 68.48; H, 4.14; N, 12.78. Found: C, 68.30; H, 3.97;
N, 12.54.
4.1.35. 1-(1-(Ferrocen-2-yl)ethylidene)-2-(4-(3-nitrophenyl)thiazol-2-
yl)hydrazine (35)
Orange powder, mp 156–158 C, 80% yield; 1H NMR (400MHz,
CDCl3): d 2.49 (s, 3H, CH3), 4.24 (s, 4H, ferrocene), 4.34 (s, 1H, ferro-
cene), 4.50 (s, 2H, ferrocene), 4.72 (s, 2H, ferrocene), 6.99 (s, 1H,
C5H-thiazole), 7.79 (s, 1H, Ar), 8.22–8.32 (m, 2H, Ar), 8.58 (s, 1H,
Ar), 12.35 (bs, 1H, NH, D2O exch.). Anal. Calcd for C21H18FeN4O2S:
C, 56.51; H, 4.07; N, 12.55. Found: C, 56.73; H, 4.29; N, 12.80.
4.1.36. 1,4-bis(1-(2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazono)ethyl)-
benzene (36)
Orange powder, mp 283–285 C, 81% yield; 1H NMR (400MHz,
DMSO-d6): d 2.37 (s, 6H, 2  CH3), 7.71–7.75 (m, 3H, 1H Ar þ 2H 2
 C5H-thiazole), 7.86 (bs, 3H, Ar), 7.87–7.88 (m, 1H, Ar), 7.89–7.90
(m, 1H, Ar), 8.16–8.18 (m, 2H, Ar), 8.33–8.35 (m, 2H, Ar), 8.75 (s,
2H, Ar), 11.45 (bs, 2H, 2  NH, D2O exch.). Anal. Calcd for
C28H22N8O4S2: C, 56.18; H, 3.70; N, 18.72. Found: C, 56.01; H, 3.96;
N, 18.55.
4.1.37. 1-(4-(3-Aminophenyl)thiazol-2-yl)-2-(1-(thiophen-2-yl)ethyli-
dene)hydrazine (37)
Red powder, mp 165–167 C, 71% yield; 1H NMR (400MHz, DMSO-
d6): d 5.15 (bs, 2H, NH2, D2O exch.), 6.50 (s, 1H, C5H-thiazole),
6.99–7.12 (m, 5H, 4H Ar þ 1H thiophene), 7.36 (s, 1H, thiophene),
7.58–7.59 (m, 1H, thiophene), 8.21 (s, 1H, CH¼), 12.06 (bs, 1H, NH,
D2O exch.). Anal. Calcd for C14H12N4S2: C, 55.97; H, 4.03; N, 18.65.
Found: C, 56.15; H, 3.84; N, 18.37.
4.2. MAO-A and MAO-B inhibition studies
4.2.1. Determination of IC50 values
The procedure for the measurement of IC50 values for the inhib-
ition of MAO has been reported32. The enzyme reactions were
prepared to a volume of 200 mM in potassium phosphate buffer at
pH 7.4 (100mM, made isotonic with KCl) and contained kynur-
amine (50 lM) and the test inhibitors (0.003–100 mM). Stock solu-
tions of the test inhibitors were prepared in DMSO and added to
the reactions to yield 4% DMSO. The enzyme reactions were initi-
ated with the addition of recombinant hMAO-A (0.0075mg pro-
tein/mL) or hMAO-B (0.015mg protein/mL) and incubated for
20min at 37 C. At endpoint, the reactions were terminated with
80 mL sodium hydroxide (2N) and the fluorescence of 4-hydroxy-
quinoline, the oxidation product of kynuramine, was measured
(kex ¼ 310; kem ¼ 400 nm)33. 4-Hydroxyquinoline was quantified
with a calibration curve (0.047–1.56 lM) and the rate of 4-hydroxy-
quinoline formation was fitted to the one site competition model
of the Prism 5 software package (GraphPad). From the resulting
sigmoidal plots, the IC50 values were estimated. All enzyme reac-
tions were carried out in triplicate and IC50 values are given as
the mean± standard deviation (SD).
4.2.2. Investigating reversibility of inhibition by dialysis
The procedure for the measurement of IC50 values for the inhib-
ition of MAO has been reported32. hMAO-B (0.03mg/mL) and the
test compounds (at 4 IC50) were incubated for 15min at 37 C to
a final volume of 0.8ml in dialysis buffer, potassium phosphate
buffer (100mM, pH 7.4) containing 5% sucrose. Stock solutions of
the test compounds were prepared in DMSO and added to the
incubations to yield 4% DMSO. The samples were dialyzed for
24 h at 4 C in 80ml of dialysis buffer using Slide-A-LyzerVR dialysis
cassettes (Thermo Scientific) with a molecular weight cut-off of
10,000 and a sample volume capacity of 0.5–3ml. The dialysis buf-
fer was replaced at 3 and 7 h after the start of dialysis. Following
dialysis, the dialysis samples were diluted twofold with the add-
ition of kynuramine to yield a kynuramine concentration and
inhibitor concentration of 50mM and 2 IC50, respectively.
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The reactions (500 mL) were incubated for 20min at 37 C and ter-
minated with NaOH (400 lL, 2 N) and water (1000mL). The fluores-
cence of 4-hydroxyquinoline in these samples was measured as
described for the IC50 determination above. As controls, MAO-B
was similarly pre-incubated and dialyzed in the absence of inhibi-
tor (negative control) as well as in the presence of the irreversible
inhibitor, (R)-()-deprenyl (positive control; IC50 ¼ 0.079 lM)34.
Undialysed mixtures of MAO-B and the test inhibitors were main-
tained at 4 C for 24 h and diluted and assayed as above. All reac-
tions were carried out in triplicate and the residual enzyme
catalytic rates are expressed as mean± SD.
4.2.3. Lineweaver–Burk plots
To construct Lineweaver–Burk plots, the enzyme reactions were
carried out to a volume of 500 mL and the concentration of MAO-
B was 0.015mg protein/mL. All enzyme reactions and activity
measurements were carried out as described above for the dialysis
experiments. The first plot was constructed in the absence of
inhibitor, while the remaining five plots were constructed in the
presence of the following concentrations: 1=4  IC50, 1=2  IC50, 3=4
 IC50, 1 IC50 and 11=4  IC50. For each line, kynuramine was
used at concentrations of 15–250 lM. The Ki value was estimated
from a plot of the slopes of the Lineweaver–Burk plots versus
inhibitor concentration (x-axis intercept equals –Ki).
4.3. Antioxidant activity evaluation
4.3.1. Phosphomolybdenum assay (PhosphoMo)
The total antioxidant activity of the compounds was evaluated by
phosphomolybdenum method according to Zengin et al.35. The
sample solution (0.3ml) was combined with 3ml of reagent solu-
tion (0.6M sulphuric acid, 28mM sodium phosphate, and 4mM
ammonium molybdate) and the absorbance was recorded at
695 nm after 90min incubation at 95 C. The EC50, which is the
effective concentration at which the absorbance was 0.5, was cal-
culated for each compound and trolox, as a reference drug.
4.3.2. Radical scavenging activity (DPPH and ABTS)
The radical scavenging effect of the compounds using the the 1,1-
diphenyl-2-picrylhydrazyl (DPPH) radical was estimated according
to Zengin et al.36. The sample solution (1ml) was added to 4ml of
a 0.004% solution of DPPH in methanol. The sample absorbance
was recorded at 517 nm after 30min incubation at room tempera-
ture in the dark.
The scavenging activity of the compounds on the ABTS radical
cation [ABTS,2,20-azino-bis(3-ethylbenzothiazoline)-6-sulphonic acid]
was measured according to the method of Zengin et al.37 with
slight modification. Briefly, ABTSþ was produced directly by reacting
a 7mM ABTS solution with 2.45mM potassium persulphate and
allowing the mixture to incubate for 12–16 h in the dark at room
temperature. Prior to initiating the assay, the ABTS solution was
diluted with methanol to an absorbance of 0.700± 0.02 at 734nm.
The sample solution (1ml) was added to the ABTSþ solution (2ml)
and mixed, and the sample absorbance was recorded at 734nm
after 30min incubation at room temperature. The corresponding
IC50 value, which is the effective concentration at which 50% of
DPPH/ABTS radicals are scavenged, was calculated for each com-
pound and trolox, as a reference drug.
4.3.3. Reducing power tests (CUPRAC and FRAP)
The cupric ion reducing activity (CUPRAC) was determined according
to the method of Zengin et al.38. The sample solution (0.5ml) was
added to a premixed reaction mixture containing CuCl2 (1ml,
10mM), neocuproine (1ml, 7.5mM), and NH4Ac buffer (1ml, 1M, pH
7.0). Similarly, a blank was prepared by adding the sample solution
(0.5ml) to a premixed reaction mixture (3ml) without CuCl2. The
absorbances of the sample and blank were subsequently recorded
at 450nm after 30min incubation at room temperature. The absorb-
ance of the blank was subtracted from that of the sample.
The FRAP (ferric reducing antioxidant power) assay was carried
out as described by Zengin et al.38. The sample solution (0.1ml)
was added to the premixed FRAP reagent (2ml) containing acet-
ate buffer (0.3M, pH 3.6), 2,4,6-tris(2-pyridyl)-s-triazine (10mM) in
40mM HCl, and ferric chloride (20mM) in a ratio of 10/1/1 (v/v/v).
The absorbance of the sample was subsequently recorded at
593 nm after 30min incubation at room temperature. Both results
were expressed as EC50 values, using trolox as a reference drug.
4.3.4. Metal chelating activity on ferrous ions
Metal chelating activity on ferrous ions was evaluated by the method
previously described39. Briefly, the sample solution (2ml) was added
to FeCl2 solution (0.05ml, 2mM). The reaction was initiated by the
addition of 5mM ferrozine (0.2ml). Similarly, a blank was prepared
by adding the sample solution (2ml) to FeCl2 solution (0.05ml,
2mM) and water (0.2ml) without ferrozine. Then, the sample and
blank absorbance were recorded at 562nm after incubation for
10min at room temperature. The absorbance of the blank was sub-
tracted from that of the sample. EDTA was used as a positive control
and this property was expressed as IC50 value for each compound.
4.4. Molecular modelling
The Schr€odinger suite 2018-140 was used to perform all molecular
modelling studies with the OPLS341 as force field. Three-dimensional
structures of the 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives 3,
4, 13, 37 were built by means the Maestro GUI and their oral
absorption and blood–brain barrier permeation were theoretically
predicted by the QikProp42 tool. Target protein structures were
obtained from the Protein Data Bank (PDB)43. In particular, the PDB
crystallographic entries 6FW044, 2Z5X45, 4M0E46, and 1P0I47 were
selected as theoretical models for hMAO-B, hMAO-A, hAChE, and
hBuChE, respectively. Each target structure was submitted to prelim-
inary manipulations by adding missing hydrogen atoms, deleting
water molecules, removing co-crystallised ligands, and fixing FAD
bonding orders. Molecular docking simulations were carried out
with Glide48 flexible ligand implementation using the extra precision
(XP) search algorithm. For the protein binding sites, a grid box of
about 64,000 A3 centred on the FAD N5 atom in the MAOs and on
catalytic Ser203 in the ChEs was considered. The default docking
scoring function was applied for ranking ligand binding modes.
Finally, ZINC PAINS Pattern Identifier49 was used to evaluate if our
derivatives could be considered as potential pan assays interfering
or aggregator compounds.
5. Results and discussion
5.1. In vitro MAO inhibition study
The synthesised compounds reported here share a similar struc-
ture, with the principal differences among compounds 1–37
occurring at the X and Y substituents as shown in Scheme 1.
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Table 1. Inhibitory activity (IC50) and selectivity index (SI) of compounds 1–35 towards hMAO-A and hMAO-B.
IC50 (μM)a SIb
Compound Hydrazone substituent hMAO-A hMAO-B
1 8.98 ± 0.621 0.095 ± 0.0043 95
2 65.0 ± 6.32 21.0 ± 2.78 3.1
3 57.2 ± 13.4 0.0068 ± 0.00046 8412
4 1.66 ± 0.133 0.0018 ± 0.00012 922
5 6.47 ± 1.25 0.0025 ± 0.00015 2588
6 94.3 ± 1.60 0.048 ± 0.0051 1965
7 23.4 ± 2.68 0.027 ± 0.0057 867
8 39.2 ± 0.121 0.015 ± 0.00057 2613
9 12.8 ± 0.421 9.11 ± 1.60 1.4
10 87.9 ± 8.59 4.63 ± 0.901 19
11 4.73 ± 0.427 0.0071 ± 0.0011 666
12 2.83 ± 0.985 0.078 ± 0.012 36
13 15.3 ± 1.11 0.0044 ± 0.00020 3477
14 51.4 ± 5.97 0.063 ± 0.018 816
15 241 ± 26.8 145 ± 50.7 1.7
16 50.7 ± 2.65 0.141 ± 0.036 360
17 9.78 ± 0.326 0.212 ± 0.022 46
18 91.9 ± 8.80 0.081 ± 0.00043 1135
19 49.4 ± 2.40 0.103 ± 0.013 480
20 156 ± 16.3 0.050 ± 0.010 3120
(continued)
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These substitutions play a fundamental role and affect the activity
and selectivity index (SI) of inhibition of the two hMAO isoforms.
SI <1 indicates selectivity for MAO-A, whereas SI >1 indicates
selectivity for the MAO-B isoform. All the tested compounds were
found to inhibit the hMAO enzymes with selectivity for the
hMAO-B isoform (Tables 1 and 2). The presence of aromatic/het-
erocyclic systems as Y moiety was effective in order to obtain
derivatives that selectively inhibit hMAO-B in the nanomolar
range. Among these compounds, the most active towards this iso-
form were the derivatives 4 (IC50 hMAO-B¼ 0.0018lM) and 5 (IC50
hMAO-B¼ 0.0025 lM), both containing methyl as X group and
respectively, thiophen-2-yl and thiophen-3-yl as Y substituent.
Comparing the inhibitory activities of compound 4 and compound
3, which contains H as X group, it can be noted that there was
only a modest decrease in MAO-B inhibition activity for 3, while a
reduction in inhibition activity was more noticeable for hMAO-A
(IC50 hMAO-A¼ 57.2 lM). This increased the SI by approximately
10-fold (from 922 for compound 4 to 8412 for compound 3). A
similar result was obtained for compound 6 where substitution on
thiophenyl ring led to a reduction in inhibition activity towards
hMAO-A compared to derivative 4. Even though hMAO-B inhib-
ition was also slightly reduced, the SI increased significantly (com-
pare 6 vs. 4). Among derivatives possessing furan as Y substituent
(1 and 2), only compound 1 exhibited inhibition activity in the
nanomolar range for hMAO-B (IC50 hMAO-B¼ 0.095 lM). The lower
activity of 2 suggests that isosteric replacement of the oxygen
atom for a sulphur is unfavourable for MAO-B inhibition (compare
2 vs. 4). Within the set of compounds containing the phenyl ring
as Y moiety, we observed the best inhibitory activity for derivative
11 (IC50 hMAO-B¼ 0.0071 lM), which contains methyl as X sub-
stituent. The absence of the methyl group (X ¼ H, compound 7)
or its elongation to X ¼ ethyl (compound 12) were detrimental
21 109 ± 8.55 0.014 ± 0.0026 7786
22 188 ± 11.1 0.024 ± 0.0065 7833
23 96.4 ± 6.88 0.336 ± 0.056 287
24 28.1 ± 3.32 4.52 ± 0.915 6.2
25 371 ± 42.8 112 ± 9.37 3.3
26 49.7 ± 2.34 13.7 ± 2.15 3.6
27 48.7 ± 1.38 9.55 ± 1.46 5.1
28 23.6 ± 0.082 0.045 ± 0.0064 524
29 123 ± 12.6 0.039 ± 0.0073 3154
30 286 ± 13.8 2.44 ± 0.634 117
31 227 ± 14.8 42.1 ± 2.98 5.4
32 236 ± 31.9 7.05 ± 3.76 33
33 4.82 ± 0.399 0.013 ± 0.0039 371
34 101 ± 8.80 80.5 ± 7.80 1.3
35 36.3 ± 2.19 0.103 ± 0.0090 352
aValues are the mean ± SD of triplicate determinations.
bSelectivity index for the MAO-B isoform, given as the ratio: (IC50 hMAO-A)/(IC50 hMAO-B).
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for MAO-B inhibition activity. Nitro-substitution on the phenyl
ring, as with compounds 8–10 and 13–15, was advantageous
when done in the ortho-position (compound 13, IC50 hMAO-
B¼ 0.0044 lM), a modification that also improved the selectivity
compared with the unsubstituted derivative 11 (SI11 ¼ 666, SI13 ¼
3477, respectively). On the other hand, substitution with an acetyl
moiety in the para-position of phenyl ring reduced activity and
selectivity as observed for compound 31 (IC50 hMAO-B¼ 42.1 lM,
SI31 ¼ 5.4). Compounds substituted with pyridine as Y moiety
(16–21) possess nanomolar activity towards hMAO-B
(0.014 lM< IC50 hMAO-B< 0.212 lM), while poor potencies were
recorded for hMAO-A inhibition, with IC50 in the micromolar range
(9.78 lM< IC50 hMAO-A< 156 lM). Most of the compounds pos-
sessing a hetero-bicyclic system as Y moiety (compounds 23–27)
showed the loss of activity and selectivity, except for compound
33 that contains a coumarin moiety. Coumarin derivatives are well
known to inhibit the hMAO enzymes as previously reported50.
Naphthyl as Y group was effective only when substituted in the
a-position (compare 28 and 29 vs. 30), while the presence of very
bulky groups such as phenanthrene (compound 34) reduced
activity towards both isoforms (IC50 hMAO-A¼ 101 lM, IC50
hMAO-B¼ 80.5 lM). Finally, we evaluated the effect of dimerisa-
tion with compound 36 and the reduction of nitro group to
obtain amine functionality with compound 37. The IC50 values
showed that the dimerisation negatively affected inhibition activ-
ity, and this is likely related to the steric hindrance in the MAO
active site. Compound 37, on the other hand, showed loss of
MAO-B inhibitory activity, which highlights the importance of the
nitro group on the meta position for this scaffold (compare 37 vs.
3). Conversely, the MAO-A inhibitory activity was not affected by
nitro reduction.
Reversibility of MAO inhibition is an important factor to con-
sider when evaluating the inhibition properties of potential inhibi-
tors. Irreversible MAO inhibitors, particularly of the MAO-A
isoform, are associated with dangerous adverse effects such as the
cheese reaction, which occurs when irreversible MAO-A inhibitors
are taken with tyramine-rich food51. To demonstrate that the 4-(3-
nitrophenyl)thiazol-2-ylhydrazone derivatives studied here are
reversible MAO inhibitors, compounds 4 and 37 were selected as
test compounds. The reversibility of MAO-B inhibition was eval-
uated by incubating MAO-B in the presence of the test com-
pounds (at a concentration of 4 IC50) for 15min, and
subsequently dialyzing the samples for 24 h. The samples were
diluted twofold and the residual MAO-B activity was measured.
For reversible inhibition, dialysis is expected to reverse inhibition
by the test inhibitors and restore enzyme activity to the level of
the negative control. The negative control consisted of similar
incubation and dialysis in the absence of inhibitor and repre-
sented 100% enzyme activity, while as positive control, these
studies were carried out in the presence of the irreversible MAO-B
inhibitor, (R)-()-deprenyl. A final experiment consisted of incuba-
tions containing MAO-B and tested inhibitors which were not dia-
lyzed, but maintained for 24 h.
The results are given in Figures 1 and 2, and show that dialysis
restored MAO-B activity for both 4 and 37, with the residual activity
at 61 and 97%, respectively. Compound 37 was thus a fully revers-
ible MAO-B inhibitor, while 4 was partially reversible, which was
likely due to tight-binding of this high potency inhibitor to the
MAO-B active site. For (R)-()-deprenyl, dialysis did not restore
enzyme activity with the residual MAO-B activity at 3% of the nega-
tive control value. In undialysed mixtures of 4 and 37, inhibition per-
sisted with the residual activity at 33 and 20%, respectively.
To provide further support for the reversibility of MAO-B inhibition
by compounds 4 and 37, a set of Lineweaver–Burk plots was con-
structed for each inhibitor at the following inhibitor concentrations:
1=4  IC50, 1=2  IC50, 3=4  IC50, 1 IC50, and 11=4  IC50. The sub-
strate, kynuramine, was used at 15–250mM for each line. The results
are given in Figures 3 and 4, and show that the Lineweaver–Burk
plots for both inhibitors are indicative of competitive, and therefore
reversible inhibition. The lines of the plots intersect on the y-axis and
a replot of the slopes versus inhibitor concentration yields a linear
line, from which the enzyme-inhibitor dissociation constant (Ki) was
estimated (Ki ¼ x-axis intercept). For compounds 4 and 37, Ki val-
ues of 0.0026 and 1.84mM are estimated.
5.2. In vitro antioxidant assays
It is a well-known that MAO-mediated oxidative metabolism of
monoamines leads to the production of hydrogen peroxide as a by-
product. Subsequently, this chemical species may be converted to
free radicals through the Fenton reaction and thus contributes to
the oxidative stress. Uncrontrolled increases in the concentrations of
these radicals initiates oxidative damage to several cellular compo-
nents. Thus, the prevention of ROS generation along with MAO
inhibition is an important strategy to prevent or limit neurotoxicity in
NDDs. The capability of the most promising MAO inhibitors of this
study to act as antioxidant agents has been evaluated in vitro by five
experimental approaches, using trolox as the reference compound.
As it can be seen from the results in Table 3, the tested compounds
showed antioxidant activity that is only slightly lower than trolox,
whereas in the reducing power assay (important for the inhibition of
the Fenton reaction between metal ions and the by-products of
MAO-mediated reaction) and total antioxidant capacity in the phos-
phomolybdenum (PhosphoMo) assay, the test and reference
Table 2. Inhibitory activity (IC50) and selectivity index (SI) of compounds 36 and 37 towards hMAO-A and hMAO-B.
Compound Structure
IC50 (µM)a SIb
hMAO-A hMAO-B
36 73.9 ± 3.32 17.6 ± 2.46 4.2
37 46.9 ± 4.12 2.67 ± 0.362 18
aValues are the mean ± SD of triplicate determinations.
bSelectivity index for the MAO-B isoform, given as the ratio: (IC50 hMAO-A)/(IC50 hMAO-B).
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compounds displayed almost comparable potencies. Chelating activ-
ity of ferrous ions, however, was almost absent for this scaffold.
These ancillary biological activities could be useful for the treatment
of multifactorial neurodegenerative diseases where oxidative stress
enhances cognitive impairment and inflammatory processes.
The proposed mechanism for the antioxidant activity of this
scaffold of compounds is depicted in Scheme 2 using DPPH/ABTS.
First the N–H group can readily donate a hydrogen radical to the
DPPH/ABTS radical and generate a new radical species which is
stabilised by resonance through the thiazole ring and
the¼C–N–N¼C moiety. The new radical can be further stabilised
by resonance through imine and thiazole structures. Since, the
antioxidant activities using the ABTS and DPPH assay are compar-
able, it may be assumed that imine and thiazole moieties can par-
ticipate in single electron transfer and lead to discrete antioxidant
activity. Moreover, other resonance structures can be present52.
5.3. Molecular modelling
Target recognition of the most interesting compounds 3, 4, 13,
and 37, as suggested by the experimental data, was investigated
by molecular modelling simulations. In agreement with experi-
mental data, docking results proposed, in general, preferred
hMAO-B recognition compared to the A isoform. Indeed, all eval-
uated compounds presented better theoretical affinity for hMAO-B
and thus more productive interactions with this isoform (Figure 5).
For compound 13 no poses in hMAO-A active site were obtained
(Figure 6).
The top poses obtained for 3, 4, and 37 showed similar orien-
tations in the MAO-B active site, with the phenyl ring substituted
at the meta position by nitro or amino group directed towards
the FAD cofactor. A similar orientation for 13 appeared in a lower
ranked pose only, since the best-scored pose showed interactions
between the nitro group and the side chains of Thr201 and Glu84
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Figure 2. Reversibility of the inhibition of hMAO-B by 37. hMAO-B and 37 (at
4 IC50) were preincubated for 15min, dialyzed for 24 h and the residual enzyme
activity was measured (37, dialyzed). hMAO-B was similarly preincubated in the
absence (No Inh, dialyzed) and presence of the irreversible inhibitor, (R)-()-dep-
renyl (depr, dialyzed), and dialyzed. For comparison, the residual hMAO activity
of undialysed mixtures of hMAO-B with 37 is also shown (37, not dialyzed).
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Figure 3. Lineweaver–Burk plots of hMAO-B activities in the absence (filled
squares) and presence of various concentrations of compound 4 (IC50 ¼
0.0018lM). For these studies the concentrations of compound 4 employed were
1=4  IC50, 1=2  IC50, 3=4  IC50, 1 IC50 and 11=4  IC50. The inset is a graph of
the slopes of the Lineweaver–Burk plots versus inhibitor concentration (Ki
¼ 0.0026lM).
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Figure 4. Lineweaver–Burk plots of hMAO-B activities in the absence (filled
squares) and presence of various concentrations of compound 37 (IC50 ¼
2.67lM). For these studies the concentrations of compound 37 employed were:
1=4  IC50, 1=2  IC50, 3=4  IC50, 1 IC50 and 11=4  IC50. The inset is a graph of
the slopes of the Lineweaver–Burk plots versus inhibitor concentration (Ki
¼ 1.84lM).
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Figure 1. Reversibility of the inhibition of hMAO-B by 4. hMAO-B and 4 (at
4 IC50) were preincubated for 15min, dialyzed for 24 h and the residual enzyme
activity was measured (4, dialyzed). hMAO-B was similarly preincubated in the
absence (No Inh, dialyzed) and presence of the irreversible inhibitor, (R)-()-dep-
renyl (depr, dialyzed), and dialyzed. For comparison, the residual hMAO activity
of undialysed mixtures of hMAO-B with 4 is also shown (4, not dialyzed).
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located at the entry of the active site. The reduction of the nitro
group did not affect the docking outcomes to a significant
degree, both in term of binding geometries and affinity energy
values. In fact, the most energetically favourable orientations of 3
and 37 were superimposable and both were involved in stacking
interactions with Tyr326 and Trp119 by means of the thiazole
ring. The binding mode of 3 was further stabilised by a hydrogen
bond between the hydrazone nitrogen atom and the Tyr326 side
chain resulting in a moderately better theoretical affinity. The sub-
stitution of the hydrazone hydrogen atom by a methyl group in
compound 4 led to a slightly different pose, characterised by the
loss of the interactions produced by the thiazolylhydrazone core.
In the hMAO-A binding site, 3 and 4 were oriented with the nitro
group toward the cofactor, but binding occurred towards to the
gorge entry. Such poses were strongly penalised with respect to
the corresponding poses in the hMAO-B active site. This observa-
tion may be due to the replacement of Tyr326 in hMAO-B by
Ile335 in hMAO-A. Furthermore, unfavourable steric clashes with
Val210 and Ile335 were present. Conversely to hMAO-B, the reduc-
tion of the nitro group in 37 induced an opposite binding mode
in which the thiazole substituent was directed towards the FAD.
Steric hindrance between 37 and Tyr407 and Tyr444 was
unfavourable for ligand-target recognition. Docking of our deriva-
tives in both ChEs (Figures 7 and 8) did not suggest a remarkable
selectivity for a particular isoform. In hAChE, 3, 4 and 13 displayed
very similar binding modes and interacted with Trp286, Tyr124,
Tyr341, and Trp86. Such poses seemed to be determined by the
m-nitrophenyl moiety which interacted with the external trypto-
phan residue (Trp286). In fact, for 37 the opposite orientation
occurred due to the loss of this productive interaction although
contacts with the tyrosine residues and with the internal trypto-
phan (Trp86) were maintained. In hBuChE, where Ala277 replaces
the hAChE Trp286, the compounds better recognised the internal
Trp82 (corresponding to Trp86 in hAChE).
Computed pharmacokinetic properties indicated that all the
derivatives evaluated may possess good absorption after oral
Table 3. Antioxidant and chelating activities of the most promising derivatives compared to the reference
drugs, EDTA and trolox.
Samples
Chelating activity
Antioxidant assays (mM)
IC50 (mM) PhosphoMo (EC50) FRAP (EC50) CUPRAC (EC50) DPPH (IC50) ABTS (IC50)
3 >5 1.84 ± 0.18 0.41 ± 0.02 0.59 ± 0.01 1.19 ± 0.01 1.05 ± 0.01
4 >5 1.68 ± 0.09 0.53 ± 0.02 0.52 ± 0.02 1.17 ± 0.01 1.04 ± 0.01
5 >5 1.16 ± 0.03 0.52 ± 0.02 0.48 ± 0.03 1.21 ± 0.01 1.05 ± 0.02
6 >5 1.25 ± 0.05 0.62 ± 0.07 0.49 ± 0.01 1.18 ± 0.01 1.08 ± 0.01
7 >5 1.29 ± 0.16 0.66 ± 0.04 0.66 ± 0.01 1.38 ± 0.01 1.04 ± 0.01
8 >5 1.70 ± 0.05 0.47 ± 0.04 0.44 ± 0.02 1.47 ± 0.01 1.04 ± 0.01
11 >5 1.46 ± 0.08 0.59 ± 0.01 0.55 ± 0.02 1.28 ± 0.01 1.04 ± 0.01
13 >5 3.10 ± 0.36 0.45 ± 0.04 0.40 ± 0.01 1.59 ± 0.01 1.04 ± 0.01
16 >5 1.13 ± 0.01 0.51 ± 0.02 0.53 ± 0.02 1.32 ± 0.01 1.06 ± 0.02
18 >5 4.70 ± 0.97 0.35 ± 0.01 0.58 ± 0.01 1.37 ± 0.01 1.04 ± 0.01
19 >5 2.64 ± 0.34 0.38 ± 0.02 0.51 ± 0.01 1.36 ± 0.01 1.04 ± 0.01
20 >5 1.77 ± 0.07 0.32 ± 0.02 0.42 ± 0.02 1.29 ± 0.01 1.04 ± 0.01
21 >5 4.48 ± 0.18 0.27 ± 0.01 0.46 ± 0.02 1.34 ± 0.02 1.04 ± 0.01
22 3.86 ± 0.29 1.28 ± 0.03 0.48 ± 0.04 0.91 ± 0.02 1.34 ± 0.01 1.04 ± 0.01
28 >5 4.93 ± 0.83 0.41 ± 0.01 0.51 ± 0.03 1.30 ± 0.01 1.05 ± 0.01
29 >5 9.39 ± 0.31 0.53 ± 0.02 0.46 ± 0.01 1.42 ± 0.01 1.04 ± 0.01
Trolox – 1.13 ± 0.05 0.16 ± 0.01 0.24 ± 0.02 0.40 ± 0.01 0.66 ± 0.02
EDTA 0.02 ± 0.001 – – – – –
Scheme 2. The proposed mechanism for the antioxidant ability of compounds 1–37.
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administration and the CNS availability of 3, 4, and 37 is compar-
able to known CNS drugs (Table 4)53. None of the considered
compounds were proposed as PAINS or aggregators by ZINC filter.
6. Conclusion
4-(3-Nitrophenyl)thiazol-2-ylhydrazones were demonstrated to be
a very interesting scaffold which can be used to design high
potency hMAO-B inhibitors, with IC50 values in the nanomolar
range. The presence of specific moieties at the hydrazone linker
gave the most selective inhibition of this isozyme. These com-
pounds are also characterised by a reversible and competitive
mode of hMAO-B inhibition, as well as by discrete antioxidant
properties. Moreover, the physical-chemical properties of the
designed molecules were predicted in silico and were found to fit
the requirements for CNS penetration. Additional interaction with
the cholinesterases (AChE and BuChE) may be possible which sug-
gests that 4-(3-nitrophenyl)thiazol-2-ylhydrazones are novel multi-
target compounds and potential leads for the design of future
therapies for NDDs.
(a) (b) 
(c) (d) 
Figure 5. Glide top poses of compounds (a) 3, (b) 4, (c) 13, and (d) 37 in the hMAO-B active site. Ligands are depicted in orange carbon polytube, the FAD is shown
in lilac coloured CPK and the most relevant residues are reported in lilac carbon polytube. Hydrogen bonds, cation–p and p–p interactions are displayed in yellow,
green and light blue respectively.
(a) (b) 
(c) (d) 
Figure 6. Glide top poses of compounds (a) 3, (b) 4, (c) 13, and (d) 37 in the hMAO-A active site. Ligands are depicted in orange carbon polytube, the FAD is shown
in lilac coloured CPK and the most relevant residues are reported in lilac carbon polytube. Hydrogen bonds, cation–p and p–p interactions are displayed in yellow,
green and light blue respectively.
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(a) (b)
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Figure 7. Glide top poses of compounds (a) 3, (b) 4, (c) 13, and (d) 37 in the hAChE active site. Ligands are reported in orange carbon polytube and the most rele-
vant residues are shown in green carbon polytube. Hydrogen bonds, cation–p and p–p interactions are displayed in yellow, green and light blue, respectively.
(a) (b)
(c) (d)
Figure 8. Glide top poses of compounds (a) 3, (b) 4, (c) 13, and (d) 37 in the hBuChE active site. Ligands are reported in orange carbon polytube and the most rele-
vant residues are shown in green carbon polytube. Hydrogen bonds, cation–p and p–p interactions are displayed in yellow, green and light blue, respectively.
Table 4. Theoretical properties and docking scores of the most interesting com-
pounds for binding to the hMAOs and hChEs.
Compound %OAa QlogBBb
Docking Scorec
hMAO-A hMAO-B hAChE hBuChE
3 95.14 0.83 0.88 9.86 6.80 6.80
4 100.00 0.70 6.10 9.02 7.03 4.71
13 92.18 1.17 0.81 4.22 5.39 5.55
37 100.00 0.47 4.53 9.45 7.02 7.04
aPercentage of oral absorption.
bBlood–brain barrier permeation as pLog(IN/OUT).
cXP docking score in kcal/mol of the top poses.
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